Golpimec (Fingolimod)

Golpimec is indicated for the treatment of adults with relapsing‑remitting multiple sclerosis (RRMS) as a disease‑modifying therapy.

• Reduces the frequency of clinical relapses in RRMS patients.
• Delays the accumulation of disability as measured by the Expanded Disability Status Scale.
• May decrease the number of new or enlarging MRI lesions in the brain and spinal cord.
• Used as part of a comprehensive disease‑management plan that includes monitoring and supportive care.
• Considered when first‑line injectable therapies are insufficient or not tolerated.

Clinical trials and post‑marketing experience have identified several adverse events associated with Golpimec; these are grouped by how frequently they occur.

Common

• Headache, fatigue, and nasopharyngitis, which are typically mild to moderate and may improve with continued therapy, and rarely require discontinuation.
• Diarrhea or abdominal pain, often transient and manageable with dietary adjustments, and usually resolve without intervention.
• Elevated liver enzymes (ALT/AST), usually reversible upon monitoring and dose adjustment, and generally normalize after drug cessation.

Serious

• Serious infections such as herpes virus reactivation, requiring prompt antiviral treatment, and may necessitate temporary suspension of therapy.
• Cardiac conduction abnormalities, including bradycardia or atrioventricular block, especially after the first dose, and may require cardiac monitoring during initiation.
• Macular edema leading to visual disturbances, necessitating ophthalmologic evaluation, and may be reversible with early detection.

Golpimec carries specific precautions that healthcare providers consider before initiating therapy and during ongoing treatment.

• Contraindicated in pregnancy; women of childbearing potential must use effective contraception.
• Not recommended for patients with active infections or a history of severe infections.
• Baseline cardiac assessment required due to risk of bradycardia, especially after first dose.
• Liver function tests should be performed before starting and periodically during therapy.
• Monitor for signs of macular edema with regular ophthalmologic examinations.
• Caution in patients with asthma or chronic obstructive pulmonary disease because of potential respiratory effects.

Golpimec may interact with other medicines; understanding these interactions helps minimize risks.

Avoid

• Live vaccines (e.g., varicella, yellow fever) because of reduced immune response.
• Strong CYP4F2 inhibitors (e.g., ketoconazole) that may increase fingolimod exposure.
• Inactivated vaccines are generally acceptable but should be administered before starting therapy or after a sufficient washout period.

Use with caution

• Antihypertensives (e.g., beta‑blockers) due to additive bradycardia risk.
• Antiplatelet or anticoagulant agents because of potential bleeding.
• Other disease‑modifying therapies for MS, requiring careful monitoring of combined immunosuppression.
• CYP3A4 inducers (e.g., rifampin) may lower fingolimod concentrations, potentially reducing therapeutic effect.